Shots:
- The US FDA has approved Degevma, a biosimilar version of Xgeva (denosumab), following FDA approval of Ponlimsi (biosimilar, Prolia) in Mar 2026, with launch of both biosimilars anticipated in coming mos.
- Approval was backed by extensive data, incl. analytical & clinical data showing similar efficacy, safety & immunogenicity profile as the reference product
- Degevma prevents bone complications in adults with advanced cancer that has spread to the bone, treats giant cell tumors of bone in adults & skeletally mature adolescents, & manages hypercalcemia of malignancy
Ref: Teva | Image: Teva | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
